Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
OBJECTIVE
To compare protection against FeLV challenge obtained following administration of 2 doses of an adjuvanted, chemically inactivated, whole FeLV (FeLV-k) vaccine with protection obtained following administration of 1 dose of an FeLV-k vaccine followed by 1 dose of a canarypox virus-vectored recombinant FeLV (rCP-FeLV) vaccine.


METHODS
Prospective study.


METHODS
Thirty-two 9-week-old domestic shorthair cats.


METHODS
Cats received 2 doses of the FeLV-k vaccine SC, 21 days apart (n = 11); 1 dose of the FeLV-k vaccine SC and, 21 days later, 1 dose of the rCP-FeLV vaccine transdermally (11); or 2 doses of physiologic saline (0.9% NaCl) solution (control; 10). Four weeks after the second vaccine dose, all cats were challenged with FeLV by means of oronasal administration. Blood samples were collected at weekly intervals beginning 21 days after challenge, and serum was tested for FeLV antigen.


RESULTS
All 10 control cats became persistently infected (ie, FeLV antigen detected in > or = 3 consecutive serum samples) following FeLV challenge, whereas only 1 of 11 cats that received 2 doses of the FeLV-k vaccine and none of the 11 cats that received 1 dose of the FeLV-k vaccine and 1 dose of the rCP-FeLV vaccine did.


CONCLUSIONS
Results suggest that protection against FeLV challenge obtained following SC administration of a single dose of an FeLV-k vaccine followed, 21 days later, by transdermal administration of a single dose of an rCP-FeLV vaccine was similar to that obtained following SC administration of 2 doses of the FeLV-k vaccine 21 days apart.
Grosenbaugh
Deborah A
DA
Merial Ltd, 115 Transtech Dr, Athens, GA 30601, USA.
Leard
Tim
T
Pardo
M Camila
MC
D000818:Animals; D028121:Canarypox virus; D002415:Cats; D007115:Immunization Schedule; D007279:Injections, Subcutaneous / Q000662:veterinary; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D011446:Prospective Studies; D015682:Retroviridae Proteins, Oncogenic / Q000008:administration & dosage / Q000276:immunology*; D013047:Specific Pathogen-Free Organisms; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods / Q000662:veterinary*; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D015682:Retroviridae Proteins, Oncogenic; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine